|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tamas K, Walenkamp A, de Vries E, van Vugt
MA, Beets-Tan RG, van Etten B, de Groot DJ and Hospers GA: Rectal
and colon cancer: Not just a different anatomic site. Cancer
treatment reviews. 41:671–679. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldberg RM, Fleming TR, Tangen CM,
Moertel CG, Macdonald JS, Haller DG and Laurie JA: Surgery for
recurrent colon cancer: Strategies for identifying resectable
recurrence and success rates after resection. Eastern Cooperative
Oncology Group, the North Central Cancer Treatment Group, and the
Southwest Oncology Group. Ann Intern Med. 129:27–35. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sardi A, Minton JP, Nieroda C,
Sickle-Santanello B, Young D and Martin EW Jr: Multiple
reoperations in recurrent colorectal carcinoma. An analysis of
morbidity, mortality and survival. Cancer. 61:1913–1919. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Beart RW: Prevention and management of
recurrent rectal cancer. World J Surg. 15:589–591. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sugarbaker PH: Update on the prevention of
local recurrence and peritoneal metastases in patients with
colorectal cancer. World J Gastroenterol. 20:9286–9291.
2014.PubMed/NCBI
|
|
7
|
Sugarbaker PH: Second-look surgery for
colorectal cancer: Revised selection factors and new treatment
options for greater success. Int J Surg Oncol.
2011:9150782011.PubMed/NCBI
|
|
8
|
André T, Louvet C, Maindrault-Goebel F,
Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E,
Izrael V and de Gramont A: CPT-11 (irinotecan) addition to
bimonthly, high-dose leucovorin and bolus and continuous-infusion
5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal
cancer. GERCOR. Eur J Cancer. 35:1343–1347. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Elias D, Goere D, Blot F, Billard V,
Pocard M, Kohneh-Shahri N and Raynard B: Optimization of
hyperthermic intraperitoneal chemotherapy with oxaliplatin plus
irinotecan at 43°C after compete cytoreductive surgery: Mortality
and morbidity in 106 consecutive patients. Ann Surg Oncol.
14:1818–1824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Elias D, Matsuhisa T, Sideris L, Liberale
G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V,
Bourget P and Ducreux M: Heated intra-operative intraperitoneal
oxaliplatin plus irinotecan after complete resection of peritoneal
carcinomatosis: Pharmacokinetics, tissue distribution and
tolerance. Ann Oncol. 15:1558–1565. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kataria T, Rawat S, Sinha S, Garg C,
Bhalla N and Negi P: Dose reduction to normal tissues as compared
to the gross tumor by using intensity modulated radiotherapy in
thoracic malignancies. Radiat Oncol. 1:12006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Broders AC: The grading of carcinoma. Minn
Med. 8:726–730. 1925.
|
|
13
|
Taylor WE, Donohue JH, Gunderson LL,
Nelson H, Nagorney DM, Devine RM, Haddock MG, Larson DR, Rubin J
and O'Connell MJ: The Mayo Clinic experience with multimodality
treatment of locally advanced or recurrent colon cancer. Ann Surg
Oncol. 9:177–185. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Olson RM, Perencevich NP, Malcolm AW,
Chaffey JT and Wilson RE: Patterns of recurrence following curative
resection of adenocarcinoma of the colon and rectum. Cancer.
45:2969–2974. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Willett CG, Tepper JE, Cohen AM, Orlow E
and Welch CE: Failure patterns following curative resection of
colonic carcinoma. Ann Surg. 200:685–690. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Curley SA, Carlson GW, Shumate CR, Wishnow
KI and Ames FC: Extended resection for locally advanced colorectal
carcinoma. Am J Surg. 163:553–559. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Michelassi F, Vannucci L, Ayala JJ,
Chappel R, Goldberg R and Block G: Local recurrence after curative
resection of colorectal adenocarcinoma. Surgery. 108:787–792.
1990.PubMed/NCBI
|
|
18
|
Chabot GG: Clinical pharmacokinetics of
irinotecan. Clin Pharmacokinet. 33:245–259. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saltz LB, Cox JV, Blanke C, Rosen LS,
Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta
N, et al: Irinotecan plus fluorouracil and leucovorin for
metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med.
343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cohen MS, Al-kasspooles MF, Williamson SK,
Henry D, Broward M and Roby KF: Combination intraperitoneal
chemotherapy is superior to mitomycin C or oxaliplatin for
colorectal carcinomatosis in vivo. Ann Surg Oncol. 17:296–303.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA:
Gynecologic Oncology Group: Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alberts DS, Liu P, Hannigan EV, O'Toole R,
Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK
and DuBeshter B: Intraperitoneal cisplatin plus intravenous
cyclophosphamide versus intravenous cisplatin plus intravenous
cyclophosphamide for stage III ovarian cancer. N Engl J Med.
335:1950–1955. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi MK, Ahn BJ, Yim DS, Park YS, Kim S,
Sohn TS, Noh JH, Heo JS, Lee J, Park SH, et al: Phase I study of
intraperitoneal irinotecan in patients with gastric adenocarcinoma
with peritoneal seeding. Cancer Chemother Pharmacol. 67:5–11. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Turcotte S, Sideris L, Younan R, Drolet P
and Dubé P: Pharmacokinetics of intraperitoneal irinotecan in a pig
model. J Surg Oncol. 101:637–642. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mundt AJ, Mell LK and Roeske JC:
Preliminary analysis of chronic gastrointestinal toxicity in
gynecology patients treated with intensity-modulated whole pelvic
radiation therapy. Int J Radiat Oncol Biol Phys. 56:1354–1360.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Uy NW, Woo SY, Teh BS, Mai WY, Carpenter
LS, Chiu JK, Lu HH, Gildenberg P, Trask T, Grant WH and Butler EB:
Intensity-modulated radiation therapy (IMRT) for meningioma. Int J
Radiat Oncol Biol Phys. 53:1265–1270. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vicini FA, Sharpe M, Kestin L, Martinez A,
Mitchell CK, Wallace MF, Matter R and Wong J: Optimizing breast
cancer treatment efficacy with intensity-modulated radiotherapy.
Int J Radiat Oncol Biol Phys. 54:1336–1344. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Engstrom PF, Arnoletti JP, Benson AB III,
Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS,
Enzinger PC, et al: NCCN Clinical Practice Guidelines in Oncology:
Colon cancer. J Natl Compr Canc Netw. 7:778–831. 2009.PubMed/NCBI
|
|
29
|
Passot G, You B, Boschetti G, Fontaine J,
Isaac S, Decullier E, Maurice C, Vaudoyer D, Gilly FN, Cotte E and
Glehen O: Pathological response to neoadjuvant chemotherapy: A new
prognosis tool for the curative management of peritoneal colorectal
carcinomatosis. Ann Surg Oncol. 21:2608–2614. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Benoist S, Brouquet A, Penna C, Julié C,
El Hajjam M, Chagnon S, Mitry E, Rougier P and Nordlinger B:
Complete response of colorectal liver metastases after
chemotherapy: Does it mean cure? J Clin Oncol. 24:3939–3945. 2006.
View Article : Google Scholar : PubMed/NCBI
|
